Praxis Precision Medicines stock price target raised by Wedbush to $33

Published 04/08/2025, 19:18
Praxis Precision Medicines stock price target raised by Wedbush to $33

Investing.com - Wedbush raised its price target on Praxis Precision Medicines Inc . (NASDAQ:PRAX) to $33.00 from $28.00 on Monday, while maintaining an Underperform rating on the stock. According to InvestingPro data, PRAX’s stock has shown significant volatility with a beta of 2.61, while trading below its Fair Value estimate.

The price target increase follows vormatrigine study results showing a 56.3% median reduction in seizures. Despite this activity, Wedbush noted challenges in interpreting the data due to the ongoing nature of the study and the absence of a placebo arm for comparison.

Safety and tolerability assessments were also difficult to evaluate without a placebo group, with Wedbush highlighting that 23% of participants discontinued the study, suggesting no meaningful difference in the adverse event profile.

Wedbush acknowledged that vormatrigine appears to have activity but questioned whether it would be commercially differentiated, stating that controlled studies will be required to determine this. The firm has introduced credit for the program in its estimates, assuming earliest market entry for the focal onset population in fiscal year 2028.

Despite the price target increase, Wedbush maintained its Underperform rating as PRAX shares continue to trade at approximately $48, significantly above the new target, with ongoing questions about vormatrigine’s place in the treatment landscape. Analyst targets for the stock range widely from $28 to $270, reflecting market uncertainty. Get deeper insights and access to 10+ additional ProTips with InvestingPro.

In other recent news, Praxis Precision Medicines has reported significant developments concerning its epilepsy treatments. The company announced positive topline results from its Phase 2 RADIANT study, where the drug vormatrigine demonstrated a 56.3% median reduction in seizure frequency among patients with focal onset seizures. Impressively, approximately 22% of patients experienced complete seizure elimination in the last 28 days of treatment. Additionally, the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to Praxis’s investigational drug relutrigine for pediatric patients with SCN2A and SCN8A developmental and epileptic encephalopathies. This designation is intended to expedite the drug’s development and regulatory review process. The decision was supported by positive data from the Phase 2 EMBOLD study, which showed a 46% reduction in monthly motor seizures. Following these announcements, Guggenheim raised its price target for Praxis to $155.00, maintaining a Buy rating, while H.C. Wainwright reiterated its Buy rating with a $105.00 price target, highlighting the growing recognition of relutrigine’s potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.